Yes. In May 2012, the British Medical journal published a Danish study of more than 600,000 women ages 15 to 49 who were using hormonal contraceptives including NuvaRing. The researchers found that NuvaRing use increased the risk of thrombosis by 6.5 times compared to women of the same age using some other contraceptive.
In 2012 the FDA released the results of another study that concluded that women who use NuvaRing run a 48 percent higher risk of blood clots.
Cardiovascular side effects enhanced by NuvaRing use included:
- Venous thromboembolic events (VTE);
- Pulmonary embolism (PE);
- Arterial thrombotic events (ATE), including heart attack, acute myocardial infarction, and ischemic stroke.